Malignancy risk on b/tsDMARDs in patients with prior malignancy history For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. https://t.co/cZwJFoqx0C https://t.co/QgoN0Qd5yz